南方医科大学学报 ›› 2026, Vol. 46 ›› Issue (4): 728-741.doi: 10.12122/j.issn.1673-4254.2026.04.02

• • 上一篇    

加味清心莲子饮通过调控KDM3C/SP1信号通路改善糖尿病肾病小鼠的肾脏损伤

谢家润1,2(), 罗燕玉1,2, 夏金金2, 王明1,2()   

  1. 1.南方医科大学中医药学院,广东 广州 510515
    2.南方医科大学珠江医院中医科,广东 广州 510280
  • 收稿日期:2025-10-02 出版日期:2026-04-20 发布日期:2026-04-24
  • 通讯作者: 王明 E-mail:983912829@qq.com;wming1999@163.com
  • 作者简介:谢家润,在读博士研究生,E-mail: 983912829@qq.com
  • 基金资助:
    国家自然科学基金(82374271);国家自然科学基金(82574746);广东省自然科学基金(2023A1515012539);广州地区中医药重大科技创新项目(2025CX004);第五批全国中医临床优秀人才研修项目(国中医药人教函[2022]1号)

Jia Wei Qingxin Lotus Seed Drink improves diabetic kidney disease in mice by regulating the KDM3C/SP1 signaling pathway

Jiarun XIE1,2(), Yanyu LUO1,2, Jinjin XIA2, Ming WANG1,2()   

  1. 1.School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China
    2.Department of Traditional Chinese Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China
  • Received:2025-10-02 Online:2026-04-20 Published:2026-04-24
  • Contact: Ming WANG E-mail:983912829@qq.com;wming1999@163.com
  • Supported by:
    National Natural Science Foundation of China(82374271)

摘要:

目的 探讨加味清心莲子饮(QISD)对糖尿病肾病(DKD)小鼠肾脏损伤的干预作用及机制。 方法 从GEO数据库中下载GSE193192数据集,筛选由晚期糖基化终末产物诱导的肾小管上皮细胞(HK-2)中差异表达的免疫基因集,利用多种分析预测药理机制。动物实验方面,选用雄性ICR小鼠,先持续性高脂饮食喂养4周后,连续腹腔注射链脲佐菌素5 d,制备DKD模型,连续灌胃低(14.46 g/kg)、中(28.92 g/kg)、高剂量(57.84 g/kg)的加味清心莲子饮12周(1次/6),以达格列净作为阳性对照,8只/组。通过HE、PAS和Masson染色观察DKD小鼠肾脏病理损伤。通过RT-qPCR和Western blotting检测KDM3C、SP1、TNF-α、MCP-1等蛋白的表达水平。在体外实验中,使用脂多糖(LPS)诱导HK-2发生炎症损伤,采用小分子抑制剂干预的方法,探索加味清心莲子饮对细胞炎性损伤的影响。 结果 动物实验结果表明,加味清心莲子饮中剂量组和高剂量组能够显著降低糖尿病肾病小鼠糖化血清蛋白、肌酐和尿素氮水平(P<0.01,P<0.001),减少糖原累积,减轻肾小球肥大,降低炎性细胞浸润。此外,加味清心莲子饮中剂量组和高剂量组能够显著降低小鼠肾脏组织中KDM3C、SP1、TNF-α和MCP-1的基因和蛋白表达(P<0.05,P<0.01,P<0.001)。细胞实验结果显示KDM3C抑制剂JIB-04的应用则能抑制TNF-α、MCP-1和ICAM-1等炎性因子的表达水平(P<0.05,P<0.001)。 结论 加味清心莲子饮可通过抑制糖尿病肾病小鼠的炎症反应改善肾脏损伤,其作用机制可能与抑制KDM3C/SP1信号通路的过度激活有关。

关键词: 数据库分析, 糖尿病肾病, 炎症, KDM3C/SP1信号通路, 加味清心莲子饮

Abstract:

Objective To investigate the therapeutic effect of Jia Wei Qingxin Lotus Seed Drink (QISD) on renal injury in mice with diabetic kidney disease (DKD) and its mechanism. Methods The immunogenes differentially expressed in renal tubular epithelial cells (HK-2) induced by late glycosylation end products were screened using GSE193192 dataset from GEO database and the pharmacological mechanisms were predicted. Male ICR mouse models of DKD established by high-fat feeding for 4 weeks and intraperitoneal streptozotocin injection for 5 days were randomized for treatment with low (14.46 g/kg), medium (28.92 g/kg) and high (57.84 g/kg) doses of QISD via gavage for 12 weeks, with dapagliflozin as the positive control drug (n=8). Penal pathologies of the mice were observed by HE, PAS and Masson staining, and renal expression levels of KDM3C, SP1, TNF-α, and MCP-1 mRNAs and proteins were detected using RT-qPCR and Western blotting. In a HK-2 cell model of lipopolysaccharide (LPS)-induced inflammatory injury, the effects of small-molecule inhibitors were tested to explore the therapeutic mechanism of QISD against cell inflammation. Results QISD treatment significantly lowered serum levels of glycated serum protein, creatinine and urea nitrogen, reduced glycogen accumulation, attenuated glomerular hypertrophy, and decreased renal inflammatory infiltration in DKD mouse models. QISD also reduces the expression levels of KDM3C, SP1, TNF‑α and MCP-1 in the kidney tissues of the mice. In LPS-induced HK-2 cells, the application of JIB-04, an inhibitor of KDM3C, obviously suppressed the expression levels of the inflammatory factors including TNF‑α, MCP-1 and ICAM-1. Conclusion QISD can ameliorate renal injury in DKD mice by inhibiting inflammatory response via suppressing excessive activation of the KDM3C/SP1 signaling pathway.

Key words: database analysis, diabetic kidney disease, inflammation, KDM3C/SP1 signaling pathway, Jia Wei Qingxin Lotus Seed Drink